
# CODE MANUAL THE SEER PROGRAM



Demographic Analysis Section, Biometry Branch, National Cancer Institute

> U.S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health

# CODE MANUAL

# THE SEER PROGRAM

# DEMOGRAPHIC ANALYSIS SECTION BIOMETRY BRANCH NATIONAL CANCER INSTITUTE

NIH Publication No. 79-1999

Revision: 6/1/79 Fffective Date: Cases First Diagnosed 1/1/79

### PREFACE

Description:

The SEER Program Code Manual is intended to be a loose-leaf publication so that revisions can be substituted easily. Pages within each segment are numbered independently using a decimal notation, the integer part indicating the field number and the decimal part indicating the pages for that particular field. Future revisions will replace entire page(s).

Arrangement:

Table of Contents SEER Program Computer Record Format Introductory Note SEER Program Code Summary Specific Instructions for Each Field (30 Fields, each a separate segment)

References:

SEER Program, Abstracting Instructions: Extent of Disease and Diagnostic Procedures, April, 1977.
SEER Program, Extent of Disease - Codes and Coding Instructions, April, 1977.
SEER Program, Geocoding for Place of Birth, April, 1977.
International Classification of Diseases for Oncology (ICD-0), World Health Organization, Geneva, 1976.

The format of the data to be submitted on magnetic tape to the National Cancer Institute by the participants in the SEER Program is as follows:

Field Number		Number of Digits	Character Position
	Basic Identification		
1	SEER Participant	2	1-2
2	Case Number and Check Digit	2 7 1	3-9
3	Type of Reporting Source	1	10
	Demographic Information		
4	Place of Residence at Diagnosis	9	11-19
5	Residence Summary	1 3 2 2 1	20
6	Place of Birth	3	21-23
7	Year of Birth	2	24-25
8	Age at Diagnosis	2	26-27
9	Race/Ethnicity		28
10	Sex	1	29
11	Marital Status at Diagnosis	1	30
	Description of This Neoplasm		
12	Date of Diagnosis	4	31-34
13	Diagnostic Information	4	35-38
14	Sequence Number	1	39
15	Primary Site	4	40-43
16	Laterality at Diagnosis	1	44
17	Blank	1	45
18	Histologic Type	6	46-51
19	Diagnostic Confirmation	1	52
20	Extent of Disease (EOD)	16	53-68
	First Course of		
	Cancer-Directed Therapy		
21	Date Therapy Initiated	4	69-72
22	Cancer-Directed Therapy	7	73-79
23	Blank	1	80
23	DIGILA	•	00
2.4	Follow-Up Information	4	81-84
24	Date of Last Follow-Up or of Death	4	81-84
25	Follow-Up Status	5	
26	Cause of Death		86-90
27	ICD Code Used for Cause of Death	1	91
<b>-</b> "	Administrative Codes		
28	Type of Follow-Up Expected	1	92
29	Coding System for Extent of Disease	1	93
30	Inter-Field Review	5	94-98

The SEER Code Manual is a limited explanation of the format and definitions of the computerized record routinely submitted by each SEER Participant to the NCI SEER Staff for analysis of the pooled data. It is, therefore, concerned only with providing description in detail sufficient to achieve consensus in coding the routinely required data. In no way does this cole manual imply any restriction on the type or degree of detailed information collected, classified, or studied at the local level.

The SEER Program is a continuation of two preceding NCI programs, the End Results Group and the Third National Cancer Survey. The working or operational definitions in these two large studies were not identical in all respects. One of the reasons for this manual is to spell out the definitions in areas where the traditions were different. Whether or not there is theoretical agreement regarding the best or proper interpretation of a particular concept, there should be a clear understanding of what has been agreed upon as a basis for common data. The interpretations presented here represent the decisions in force at this time.

"What is a Diagnosis of Cancer?"

The simplest way to state the answer is that a patient has cancer if a recognized medical practitioner says so. Then the question changes to "How can one tell from the medical record that the physician has stated a cancer diagnosis?" In most cases the patient's record clearly presents the diagnosis by use of specific terms which are synonymous with cancer. However, not always is the physician certain or the recorded language definitive. SEER rules concerning the usage of vague or inconclusive diagnostic language are as follows:

The ambiguous terms "probable", "suspect", "suspicious", "compatible with", or "consistent with" ARE to be interpreted as involvement by tumor.

The ambiguous terms "questionable", "possible", "suggests", or "equivocal" ARE NOT to be interpreted as involvement by tumor.

"How Unchangeable are the Diagnosis Items?"

Most of the diagnostic information items are restricted to information available or procedures performed within the time limits defined for each item. However, with the passage of time the patient's medical record gets more complete in regard to information originally missing or uncertain. It is therefore established practice to accept the thinking and information about the case at the time of the latest submission, or the most complete or detailed infomation. Thus, there may be changes in the coding of primary site, histology, extent of disease, residence, etc., as the information becomes more certain. There may be cases reported originally as cancer, especially if the initial report was a death certificate or one with ambiguous terms as listed above, which later information indicates never was a malignancy. These cases must be deleted from the file.

"What is CANCER so far as Reporting to SEER is Concerned?"

The SEER Program definition of cancer is explicitly defined in Field 18, Histologic Type, as follows:

All cases with a behavior code of "2" or "3" in the International Classification of Diseases for Oncology (ICD-0) are reportable neoplasms with the following exclusions for cancers of the skin (Sites 173.0 - 173.9) only:

8000-8004 Neoplasms, malignant, NOS of the skin
8010-8043 Epithelial carcinomas of the skin
8050-8082 Papillary and Squamous cell carcinomas of the skin
8090-8110 Basal cell carcinomas of the skin

Note that the above lesions ARE reportable for skin of the labia, clitoris, vulva, prepuce, penis, and scrotum (Sites 184.1, 184.2, 184.3, 184.4, 187.1, 187.2, 187.7).

Note also that if a "0" or "1" behavior code term in ICD-0 is verified as in-situ, "2", or malignant, "3", by a pathologist, these cases are reportable.

"What is the Policy when there is More Than One Cancer?"

The determination of how many primary tumors a patient has is, of course, a medical decision, but operational rules are needed in order to insure consistency of reporting by all participants. Basic factors include the site of origin, the date of diagnosis, the histologic type, the behavior of the neoplasm (i.e., in-situ vs. malignant), and laterality.

In general, if there is a difference in the site where the tumor originates, it is fairly easy to determine whether it is a separate primary, regardless of dates of detection and of differences in histology.

Likewise, if there is a clearcut difference in histology, other data such as site and time of detection are not essential. In some neoplasms, however, one must be careful since different histologic terms are used to describe progessive stages or phases of the same disease process.

Vi

The following definitions and rules are used to determine the number of independent primary tumors:

# **DEFINITIONS:**

- 1. Site: For colon, rectum, bone, connective tissue, and skin, each subcategory as delineated in the International Classification of Diseases for Oncology (ICD-O) is considered to be a separate site. For all other sites, each category as delineated in ICD-O is considered to be a separate site. For example, Transverse colon (ICD-O site code 153.1) and Descending colon (153.2) are each considered to be sites while Trigone of urinary bladder (188.0) and Lateral wall of urinary bladder (188.2) are considered to be subsites of the urinary bladder. Bach side of a paired site is considered to be a separate site unless metastatic. Code a lymphoma to an extra-nodal site when there is no nodal involvement of any kind or there is a medical statement that the origin was in an extra-nodal site.
- 2. Histologic type: Differences in histologic type refer to differences in the first three digits of morphology as delineated in ICD-0.
- 3. Simultaneous: Diagnoses within two months of each other.

### RULES:

- 1. A single lesion of one histologic type is considered a single primary even if the lesion crosses site boundaries.
- 2. A single lesion with multiple histologic types is to be considered as a single primary and is coded to the highest histology code number in the absence of an appropriate "mixed histology code" including those given in the rules below.
- 3. If a new cancer of the same histology as an earlier one is diagnosed in the same site within two nonths, consider this to be the same primary tumor. If a new cancer of the same histology is diagnosed in the same site after two months, consider this new cancer as a separate primary unless stated to be recurrent or metastatic.
- 4. Simultaneous multiple lesions of the same histologic type within the same primary site will be considered a single primary. Further, if one lesion has a behavior code of in-situ and another a behavior code of malignant, still consider this to be a single primary whose behavior is malignant. Multiple lesions of the same histologic type occurring in different sites are considered to be separate primaries unless stated to be metastatic.

- 5. Multiple lesions of different histologic types within a single site are to be considered separate primaries whether occurring simultaneously or at different times. Similarly, multiple lesions of different histologic types occurring in different sites are considered separate primaries whether occurring simultaneously or at different times. The following are exceptions to this rule:
  - a) For multiple lesions within a single site occurring within two months, if one lesion is stated to be (adeno)carcinoma, NOS and the second lesion is stated to be a more specific (adeno)carcinoma, consider this to be a single primary and code to the more specific (adeno)carcinoma.
  - b) Within each breast the following combinations of ductal and lobular carcinoma occurring within two months of each other are to be considered a single primary and the histology coded accordingly.
    - 1) Infiltrating duct carcinoma (8500/3) and lobular carcinoma (8520/3) code to histology 8522/3.
    - Infiltrating duct carcinoma (8500/3) and lobular carcinoma in-situ (8520/2) code to histology 8523/3.
    - 3) Intraductal carcinoma (8500/2) and lobular carcinoma (8520/3) code to histology 8524/3.
    - 4) Intraductal carcinoma (8500/2) and lobular carcinoma insitu (8520/2) code to 8522/2.

Note that for female breast if the ductal and lobular lesions are reported to occur in different quadrants of the same breast, the appropriate site code is 174.9. If the ductal lesion occurs in one breast and the lobular lesion occurs in the opposite breast, these are considered to be two primaries whether diagnosed within two months or not.

- c) Within each breast, a combination of Paget's disease with intraductal carcinoma should be coded to 8543/3.
- If only one histologic type is reported and if both sides of 6. a paired site are involved within two months of diagnosis, a determination must be made as to whether the patient has one or two independent primaries. (This determination is generally made by the pathologist based on whether areas of in-situ are seen in each side of the pair.) If it is determined that there are two independent primaries, two records are to be submitted each with the appropriate laterality and extent of disease information. If it is determined that there is only one primary, laterality should be coded according to the side in which the single primary originated and a single record submitted. If it is impossible to tell in which of the pair the single primary originated, laterality should be coded as a "4" and a single record submitted. The one exception to this rule is that paired involvement of the ovaries in which only a single histology is reported is always considered to be a single primary.

Field Character Number Position Code Description Basic Identification 1 1-2 SEER Participant A specific two-digit identification of each participant in the SEER Program. 01 San Francisco-Oakland SMSA 02 Connecticut 20 Metropolitan Detroit 21 Hawaii 22 Iowa 23 New Mexico 24 Metropolitan New Orleans 25 Seattle (Puget Sound) 26 Utah 27 Metropolitan Atlanta 28 Puerto Rico 33 Arizona Navajo 37 Rural Georgia 3-9 Case Number and Check Digit 2 A six-digit number assigned by the participating SEER registry followed by a seventh digit, i.e., check digit, calculated according to an algorithm acceptable to the SEER staff. Type of Reporting Source 3 10 1 Hospital Inpatient 2 Clinic (Hospital or Private) 3 Laboratory (Hospital or Private) 4 Private Medical Practitioner (LMD) 5 Nursing/Convalescent Home Autopsy Only (Diagnosed at Autopsy) 6 7 Death Certificate Only (Including no information on follow-back) Note: Codes 1-2 take precedence over codes 3-5; code 6 takes precedence over code 7. Demographic Information 4 Place of Residence at Diagnosis 11-19 11-13 County Code Census Tract 14-19 5 20 Residence Summary 0 Non-resident of Incidence Reporting Area 1 Resident of Incidence Reporting Area

Field Number	Character Position	Code Description		
	Demograpi	hic Information (continued)		
6	21-23	Place of Birth See SEER booklet "SEER Program Geocoding for Place of Birth".		
7	24-25	Year of Birth Last two digits of birth year Unknown		
8	26-27	Age at Diagnosis (Age at last Birthday) 00 Less than one year old 01 One year old, but less than two years • • 98 Ninety-eight years old or older 99 Unknown Age		
9	28	Race/Ethnicity O Caucasian NOS 1 Caucasian of Spanish surname or origin 2 Black 3 American Indian or Alaskan native 4 Chinese 5 Japanese 6 Filipino 7 Hawaiian 8 Other 9 Unknown		
10	29	Sex 1 Male 2 Female 3 Other (Hermaphrodite) 4 Transsexual 9 Not Stated		
11	30	Marital Status at Diagnosis 1 Single (never married) 2 Married 3 Separated 4 Divorced 5 Widowed 9 Unknown		

Field Number	Character Position	Code Description
	Descript	ion of this Neoplasm
12	31-34	Date of Diagnosis
	31-32	Month 01-12 Month 99 Unknown
	31-34	Year Last two digits of year 99 Year Unknown
13	35-38	Diagnostic Information
	35-37 38	Blank Description of Pathologic Investigation
14	39	Sequence Number O One primary only Pirst of two or more primaries Second of two or more primaries Eighth or later primary Unspecified sequence number
15	40-43	Primary Site
	40-42	See the International Classification of Diseases for Oncology (ICD-0, 1976) Topography section for the primary site. Place the last 3 digits in CP 40-42, i.e., drop the 1st digit, "1", and the decimal point.
	43	Blank
16	44	Laterality at Diagnosis 0 Not a paired site 1 Right: origin of primary 2 Left: origin of primary 3 Only one side involved, right or left origin unspecified 4 Bilateral involvement, lateral origin unknown: stated to be single primary 9 Paired site, but no information concerning laterality
17	45	Blank

SUMMARY SEER CODE SUMMARY

Field Number	Character Position	Code Description
	Descripti	on of This Neoplasm (continued)
18	46-51	Histologic Type
		See the International Classification of Diseases for Oncology (ICD-O) Morphology Section for histologic type including behavior and grading.
	46-49 50 51	First four digits of M code number. Behavior code - see p. 20 of ICD-0. Grading or Differentiation - see p. 20 of ICD-0.
19	52	Diagnostic Confirmation 1 Positive histology 2 Positive exfoliative cytology, no positive histology 4 Positive microscopic confirmation, method not specified 6 Direct visualization without microscopic confirmation 7 Radiography without microscopic confirmation 8 Clinical diagnosis only 9 Unknown whether or not microscopically confirmed
20	53-68	Extent of Disease (EOD) There are three EOD schemes as indicated in the following format by Fields 20A, 20B, and 20C. Use the numeric list of primary sites on page 20.1 of this manual to determine which one of the EOD coding schemes should be used.
20 A	53-68 53-66 67-68	SEER Non-Specific EOD Scheme Blank Non-Specific Code
OR 20B	53-68 53-66 67-68	SEER Two-Digit Site-Specific EOD Scheme Blank SEER Two-Digit Site-Specific Code
0R 20C	53-68	SEER Expanded Site-Specific EOD Scheme
	53-54 55 56-59 60 61-62 63-64 65 66-68	Tumor Size Blank Direct Extension of Primary Tumor Site-Specific Information Regional Lymph Node Involvement Distant Lymph Node Involvement Distant Site Involvement Blank xii

Field Number	Character Position	Code Description
	First Co	ourse of Cancer-Directed Therapy
21	69-72	Date Therapy Initiated
		0000 No cancer-directed therapy
	69-70	Nonth 01-12 Month 99 Unknown
	71-72	Year Last two digits of year 99 Unknown
22	73-79	Cancer-Directed Therapy
		0000000 Only symptomatic or supportive therapy
	73	Surgery O None 1 Surgical Resection 8 Surgery recommended, unknown if performed 9 Unknown
	74	Radiation O None 1 Beam Radiation 2 Other Radiation 3 Combination of 1 and 2 7 Radiation, NOS 8 Radiation recommended, unknown if administere 9 Unknown
	75	Radiation Sequence with Surgery
		<pre>If treatment consisted of both surgery and radiation, i.e., CP 73 = 1 AND CP 74 = 1,2,3, or 7, code: 2 Radiation before surgery 3 Radiation after surgery 4 Radiation both before and after surgery 5 Sequence unknown, but both were given</pre>
		All other cases, code: 0 Not applicable. This includes the following combinations of CP 73 and CP 74:
		CP 73 CP 74 0,8,9 0-9 1 0,8,9

SEER Program

	Character		
Number	Position	Code	Description
	First Co (conti		ncer-Directed Therapy
	76	Chemothe	rapy
		0 None	
		1 Chemo	otherapy
		8 Chemo	therapy recommended, unknown if
			unistered
		9 Unkno	WR
	77	Hormonal	Therapy
		0 None	•
			nes (including NOS)
			rine Surgery (if cancer is of
			ther site)
			nation of 1 and 2
		4 Endoc sit	rine Radiation (if cancer is of another
			nation of 1 and 4
			nation of 2 and 4
			nation of 1 and 2 and 4
		8 Hormo	nal therapy recommended, unknown administered
		9 Unkno	an a
	78	Immunoth	erapy
		0 None	
			otherapy
			otherapy recommended, unknown
			administered
		9 Unkno	Wn
	79	Other Ca	ncer-Directed Therapy
		0 None	(No cancer-directed therapy except as ed in CP 73-78)
		1 Other der	cancer-directed therapy (including moplaning hyperbaric oxygen as unct, etc.)
		2 Exper	imental cancer-directed therapy (not luded in CP 73-78)
			e-blind study, code not yet broken
		7 Unpro	ven therapy (including laetrile,
			biozen, etc.) cancer-directed therapy recommended,
		unk	nown if administered
		9 Unkno	Wn

23 80 Blank

	Character Position	Code Description
	Follow-Up	Information
24	81-84	Date of Last Follow-Up or Death
	81-82	Month 01-12 Month 99 Unknown
	83-84	Year Last two digits of year
		Note: There should be NO use of code for unknown year in Field 24.
25	85	<ul> <li>Follow-Up Status</li> <li>Alive - No evidence or complete remission of cancer</li> <li>Alive - With any cancer</li> <li>Alive - Cancer status unknown</li> <li>Dead - No evidence or complete remission of cancer at death</li> <li>Dead - This cancer present at death (even if other cancer is also present)</li> <li>Dead - No evidence or complete remission of this cancer, but another cancer present at death</li> <li>Dead - Cancer present at death, but it cannot be established whether it was this one or another</li> <li>Dead - Indeterminate whether cancer was present at death</li> </ul>
26	86-90 86-89	Cause of Death (According to Death Certificate) Cause of Death (four digits). Also use the following special codes with 7th, 8th or 9th Revision: 0000 Patient alive at last contact
	90	7777 Death certificate not available 7969 Death certificate available but cause of death not coded Blank
27	90 91	ICD Code Used for Cause of Death (Field 26 O Patient Alive at Last Follow-Up 7 Seventh Revision of ICD 8 Eighth Revision of ICD 9 Ninth Revision of ICD

# SUBMARY

SEER Program

Field Number	Character Position	Code Description
	Administ	rative Codes
28	92	Type of Follow-Up Expected 1 Case not in active follow-up - "Autopsy Only" and "Death Certificate Only" cases 2 Case is (or was) in active follow-up
29	93	Coding System for Extent of Disease (Field 20) 0 SEER Non-Specific EOD Code in CP 67-68; blanks in CP 53-66 1 Two Digit Site-Specific EOD Code in CP 67- 68; blanks in CP 53-66 2 SEER Expanded Site-Specific EOD Code in CP 53-65 (only for authorized sites); blanks in CP 66-68
30	94-98	Inter-Field Review
	94	Site-Type Edit 1 Reviewed: there is an apparent anomaly be- tween the coding of primary site and his- tologic type. No need to review again.
	95	Histology 1 Reviewed: the behavior code of the hist- ology is designated as benign or uncertain in ICD-0 but upon review the behavior code remains as in-situ or malignant.
	<b>96</b> -98	Blank

\*\*\*\*\*

Each registry participating in the SEER Program is assigned a specific two-digit number.

CP 1-2

	1-2	Area Covered/ Year Reporting	
Cođe	Contractor	Started	Name
01	California State Department of Health	5 counties/ 1973	San Francisco- Oakland SMSA
02	Connecticut State Department of Health	Entire state/ 1973	Connecticut
2)	Michigan Cancer Foundation	3 counties/ 1973	Metropolitan Detroit
21	Hawaii Medical Association	Entire state/ 1973	Hawaii
22	University of Iowa	Entire state/ 1973	Iowa
23	University of New Mexico	Entire state/ 1973	New Mexico
24	Louisiana Health, Social and Rehabilitation Service Administration	3 parishes/ 1974	Metropolitan New Orleans
25	Fred Hutchinson Cancer Research Center	13 counties/ 1974	Seattle (Puget Sound)
26	University of Utah	Entire state/ 1973	Utah
27	Atlanta Cancer Surveillance Center	5 counties/ 1975	Metropolitan Atlanta
28	Puerto Rico Department of Health	Entire commonwealth/ 1973	Puerto Rico
33	University of New Mexico	Arizona portion Navajo Nation/ 1973	Arizona Navajo
37	Atlanta Cancer Surveillance Center	10 counties/ 1978	Rural Georgia

The first six digits of Field 2, CP 3-8, are reserved for the case number used by the SEER Participant to identify the patient. The seventh digit, CP 9, is for a check-digit referring to that case number.

Each computer record pertaining to the same patient should have an identical entry in Field 2.

CP 3-8 Case Number:

If the case number is less than six digits, enter leading zeros to create a six-digit entry. For example, Case #7034 will be coded as 007034.

Use no blanks in any of the positions CP 3-8.

CP 9 Check-Digit:

For our purposes, a check-digit is a number derived from the elements of a numerical code and is then appended to that code. In a sense, it becomes part of the code.

The entire field, including the check-digit, is checked by recalculating the check-digit. If the newly calculated check-digit does not match the recorded check-digit, an error of some kind is indicated. While not all errors can be detected by this type of rechecking, most transposing and many transcribing errors will be picked up.

Code:

1 Hospital Inpatient

2 Clinic (Hospital or Private)

3 Laboratory (Hospital or Private)

4 Private Medical Practitioner (LMD)

5 Nursing/Convalescent Home

6 Autopsy Only (Diagnosed at Autopsy)

7 Death Certificate Only (Including no information on follow-back and Coroners' cases)

General:

This field helps explain why some records are incomplete. Probably the most important use for Field 3 is to identify those cases coded 6 or 7 which are excluded from studies of survival, but included in studies of incidence.

Specific:

Codes 1 and 2 take precedence over codes 3 through 5 if there are several reporting sources. In other words, the hospital record for an inpatient with a cancer diagnosis (before death) takes precedence over all other types of reports.

Code 6, Autopsy Only, means that the cancer was not diagnosed even as a clinical diagnosis while the patient was alive. If the patient was an inpatient with another admitting diagnosis and the autopsy at the same hospital disclosed the cancer for the first time, code 6 is proper. Autopsy findings take precedence over death certificate information, i.e., code 6 takes precedence over code 7. However, a clinical diagnosis of cancer at any of the sources coded 1-5 has priority over confirmation at autopsy.

Code 7, Death Certificate Only, is used only when "follow-back" activities have produced no other medical reports - the death certificate is truly the only source of information. Often a case is reported first via the death certificate, but later registry action yields missing or additional medical reports. Such additional reports take precedence. For Death Certificate Only cases, Date of Diagnosis (Field 12) should be the date of death, Diagnostic Information (Field 13) should be left blank, Diagnostic Confirmation (Field 19) should be coded "9", Extent of Disease (Field 20, CP 67-68) should be coded "--", and Coding System used for Extent of Disease (Field 29) should be coded "0".

Page 3.1

Field 4 CP 11-19

Field 4 provides nine digits (CP 11-19) for the coding of residence at diagnosis. The Field is divided into two subfields, the first (CP 11-13) to indicate County, and the second (CP 14-19) to indicate Census Tract. Census Bureau statistics by census tract provide much of the socioeconomic data easily available for evaluation studies. The most meaningful data are provided for census tracts within a SMSA (Standard Metropolitan Statistical Area), but a SEER Participant may cover an area with more than one SMSA. Therefore, the County Code is provided for identification of the SMSA and its component census tracts. It may also be useful in the coding of residents of the covered area outside a specific SMSA.

Census tract should be right justified. Assume that the decimal point is located between CP 17 and CP 18. Thus, census tract 409.6 would be coded 040960 in CP 14-19.

There is enough coding space in Field 4 to accommodate the coding of residence for non-residents of the SEER area. However, there are no requirements at this time for such coding.

Specific:

CP 11-13 County code

CP 14-19 Census tract: If not reporting this field, CP 14-19 = 000000.

If a person is known to be a resident of a particular SEER area, but the exact county is unknown, code 999 in CP 11-13.

The following are the valid county codes (CP 11-13).

	County	
SEER Area	Code	County
California	001	Alameda
	013	Contra Costa
	041	Marin
	075	San Francisco
	081	San Mateo
Connecticut	001	Fairfield
	003	Hartford
	005	Litchfield
	007	Middlesex
	009	New Haven
	011	New London
	013	Tolland
	015	Windham

Fie	1	đ	4
CP	1	1-	19

Georgia	063	Clayton
Metropolitan	067	Cobb
Atlanta	089	De Kalb
Actalica	121	Fulton
	135	Gwinnett
	133	GWINHELL
Georgia	125	Glascock
Rural Counties	133	Greene
	141	Hancock
	159	Jasper
	163	Jefferson
	211	Morgan
	237	Putnam
	265	Taliaferro
	301	Warren
	303	Washington
	303	a dout ng ton
Havaii	001	Hawaii
	003	Honolulu
	307	Kauai
	009	Maui
Iowa	001	Adair
	003	Adams
	005	Allamakee
	007	Appanoose
	009	Audubon
	011	Benton
	013	Black Hawk
	015	Boone
	017	Bremer
	019	Buchanan
	021	Buena Vista
	023	Butler
	025	Calhoun
	<b>J</b> 2 <b>7</b>	Carroll
	029	Cass
	031	Cedar
	033	Cerro Gordo
	035	Cherokee
	037	Chickasaw
	039	Clarke
	041	Clay
	043	Clayton
	045	Clinton
	047	Crawford
	049	Dallas
	051	Davis
	053	Decatur

Iowa	(continued)	055	Delaware
	•	057	Des Moines
		059	Dickinson
		061	Dubuque
		063	Eamet
		065	Fayette
		067	Floyd
		069	Franklin
		071	Fremont
		073	Greene
		075	Grundy
		077	Guthrie
		079	Hamilton
		081	Hancock
		083	Hardin
		085	Harrison
		087	Henry
		089	Howard
		091	Humbolt
		093	Ida
		095	Iowa
		097	Jackson
		099	Jasper
		101	Jefferson
		103	Johnson
		105	Jones
		107	Keokuk
		109	Kossuth
		111	Lee
		113	Linn
		115	Louisa
		117	Lucas
		119	Lyon
		121	Madison
		123	Mahaska
		125	Marion
		127	Marshall
		129	Mills
		131	Mitchell
		133	Monona
		135	Nonroe
		137	Montgomery
		139	Muscatine
		141	O'Brien
		143	Osceola
		145	Page
		147	Palo Alto
		149	Plymouth

.

CP 11-19

.

Iowa (continued)	151	Pocahontas
	153	Polk
	155	Pottawattamie
	157	Poweshiek
	159	Ringgold
	161	Sac
	163	Scott
	165	Shelby
	167	Sioux
	169	Story
	171	Тала
	173	Taylor
	175	Union
	177	Van Buren
	179	
	181	Wapello Wappel
	183	Warren
		Washington
	185	Wayne
	187	Webster
	189	Winnebago
	191	Winneshiek
	193	Woodbury
	195	Worth
	197	Wright
Louisiana	051	Jefferson
	071	Orleans
	087	St. Bernard
Hichigan	099	Macomb
	125	Oakland
	163	Wayne
Navajo Nation	001	Apache
(Arizona)	005	Coconino
	017	Navajo
New Mexico	001	Bernalillo
	003	Catron
	005	Chaves
•	007	Colfax
	009	Curry
	011	De Baca
	013	Dona Ana
	015	Eddy
	017	Grant
	019	Guadalupe
	021	Harding
	023	Hidalgo
	025	Lea

CP 11-19

****		
New Mexico	027	Lincoln
(continued)	028	Los Alamos
	029	Luna
	031	McKinley
	033	Мога
	035	Otero
	037	Quay
	039	Rio Arriba
	041	Roosevelt
	043	Sandoval
	045	San Juan
	047	San Miguel
	049	Santa Fe
	051	Sierra
	053	Socorro
	055	Taos
	057	Torrance
	059	Union
	061	Valencia
Utah	001	Beaver
	<b>903</b>	Box Elder
	005	Cache
	007	Carbon
	009	Daggett
	011	Davis
	013	Duchesne
	015	Emery
	017	Garfield
	019	Grand
	021	Iron
	023	Juab
	025	Kane
	02 <b>7</b>	Millard
	029	Morgan
	031	Piute
	033	Rich
	035	Salt Lake
	037	San Juan
	039	Sanpete
	041	Sevier
	043	Sumnit
	045	Tooele
	047	Uintah
	049	Utah
	051	Wasatch
	053	Washington
	055	Wayne
	057	Weber
	434	う くち かか

-----

Fie	1d	4
CP	11-	- 19

-----

Washington	009	Clallam
-	027	Grays Harbor
	029	Island
	031	Jefferson
	033	King
	035	Kitsap
	045	Mason
	053	Pierce
	055	San Juan
	057	Skagit
	061	Snohomish
	06 <b>7</b>	Thurston
	073	Whatcom
Puerto Rico	001	Entire Commonwealth

.

.

Field 5 refers to the residence of this patient at diagnosis for this cancer.

- 0 Non-resident of Reporting Area
- 1 Resident of Reporting Area

Field 6 indicates place of birth. It includes states within the United States as well as foreign countries.

Code:

See "SEER Program Geocoding for Place of Birth" for coding this three-digit field.

Field 7 indicates the year of the patient's birth.

Code:

Last 2 digits of the patient's birth year.

-- Unknown

If age at diagnosis and year of diagnosis are known, but year of birth is unknown, then year of birth should be calculated and so coded.

-. -

Field 8 represents the age of the patient at diagnosis for this cancer. Age is measured in completed years of life, i.e., age at last birthday. Code: Number of years of age at last birthday Less than one year old 00 01 One year old, but less than two years old . ٠ 97 Ninety-seven years old, but less than ninety-eight 98 Ninety-eight years old or older Unknown age 99

If year of birth and year of diagnosis are known, but age is unknown, calculate age at diagnosis.

- 0 Caucasian NOS
- 1 Caucasian of Spanish surname or Spanish origin
- 2 Black
- 3 American Indian or Alaskan Native
- 4 Chinese
- 5 Japanese
- 6 Filipino
- 7 Hawaiian
- 8 Other
- 9 Unknown

.

- 1 Male
- 2 Female
- 3 Other (Hermaphrodite)
- 4 Transsexual
- 9 Not stated

Field 11 indicates the marital status of the patient at diagnosis for this cancer.

- Single (never married) 1
- 2 Married
- 3 Separated
- 4 Divorced
- 5 Widowed
- 9 Unknown

### Code:

CP 31-32 Month

- 01 January 02 February 03 March 04 April 05 May 06 June 07 July 08 August 09 September
- 10 October
- 11 November
- 12 December
- 99 Unknown
- CP 33-34 Year

- -

Last two digits of year

99 Unknown

Definition:

The date in Field 12 refers to the first diagnosis of this cancer by any recognized medical practitioner. This is often a clinical diagnosis and may not ever be confirmed histologically. Even if confirmed later, the date in Field 12 refers to the date of the first clinical diagnosis and not to the date of confirmation. If upon medical and/or pathological review of a previous condition the patient is deemed to have had cancer at an earlier date, then the earlier date is the date of diagnosis, i.e., the date of diagnosis is back-dated.

General:

In the absence of an exact date of diagnosis, the best approximation is acceptable. Approximation is preferred to coding the month and/or year as unknown:

a) For patients diagnosed while in a hospital, the date of admission for that hospitalization may be used as the date of diagnosis.

b) If it seems that the patient was hospitalized within a "reasonable time" (approximately one month or less) from true date of diagnosis by the referring physician or referring hospital, the date of first admission may be used as the date of initial diagnosis. Field 12 CP 31-34

c) If the only information is "Spring of", "Middle of the year", "Fall", approximate these as April, July, and October respectively. For "Winter of" it is important to discover whether the beginning or end of the year is meant before approximating the month.

d) If there is no basis for an approximation, code the month of diagnosis as 99 in CP 31-32.

e) If necessary, approximate the year. If no approximation is possible, code year of diagnosis as 99 in CP 33-34. If code 99 is used in CP 33-34, code 99 should also be used in CP 31-32.

f) Date of first cancer-directed therapy may be used as the date of diagnosis if the cancer-directed therapy has been initiated and cancer is later confirmed, but prior to therapy the diagnosis was not definitive.

g) The date of diagnosis for "Death Certificate Only" cases is the date of death. If later follow-back results in more definitive information on the date of diagnosis, this date should be changed, and then this case is no longer a "Death Certificate Only" case. \_\_\_\_\_

CP 35-37 Blank

CP 38 Description of Pathologic Investigation

> Procedures requiring observation of tissue and cells for the following sites: stomach, colon/rectum, bronchus and lung, malignant melanoma, breast, cervix uteri, corpus uteri, prostate, bladder, lymph nodes and lymphoid tissue (Hodgkin's Disease and non-Hodgkin's lymphoma).

· · ·

General:

This field evaluates the relative reliability of Extent of Disease information on the basis of the pathologic examinations. It should be limited, just as is extent of disease, to all pathologic examinations by the end of the first hospitalization for definitive SURGICAL resection if done within two months of diagnosis, or two months after diagnosis for ALL OTHER CASES--both treated and untreated.

If a patient has radiation therapy followed by definitive surgery within two months of diagnosis, include all information available through definitive surgery.

If an excisional biopsy, D and C, cone biopsy, lymphadenectomy, TUR (prostate or bladder), or a polypectomy is followed by further definitive therapy within two months of diagnosis, include all information available through the definitive therapy.

Specific:

Only the sites specified above are to be coded in CP 38. For all other sites this field is to be left blank. The site-specific codes follow.

STOMACH (excluding cardia-esophageal junction) 510-519 0 None 1 Cytology of primary site (including brushings and washings) 2 Biopsy of primary site (includes biopsy done during endoscopy or exploratory surgery) 3 Biopsy or resection of direct extension and/or regional node(s) 4 (3) and (2)5 Resected primary site 6 Resected primary site and regional node(s) 7 Cytology of distant site 8 Biopsy or resection of distant site and/or distant node(s) 9 (7 or 8) with any of (2-4)(7 or 8) with (5 or 6) З COLON AND RECTUM 530-534, 536-537, 540-541 0 None 1 Cytology of primary site (including washings) 2 Biopsy of primary site (includes biopsy done during endoscopy or exploratory surgery) 3 Biopsy or resection of direct extension and/or regional node(s) 4 (3) and (2)5 Resected primary site 6 Resected primary site and regional node(s) 7 Cytology of distant site Biopsy or resection of distant site and/or distant 8 node(s) 9 (7 or 8) with any of (2-4)& (7 or 8) with (5 or 6)

BRONCHUS AND LUNG (excluding carina) 622-629 0 None 1 Cytology of primary site (including sputum, brushings, and washings) 2 Biopsy of primary site (includes biopsy done during endoscopy or exploratory surgery) Biopsy or resection of direct extension and/or regional 3 node (s) 4 (3) and (2)Resected primary site 5 6 Resected primary site and regional node(s) 7 Cytology of distant site Biopsy or resection of distant site and/or distant 8 node (s) 9 (7 or 8) with any of (2-4)3 (7 or 8) with (5 or 6) MALIGNANT MELANOMA OF SKIN 733-737, 841-844, 871-872, 874, 877 HISTOLOGY: 8720 thru 8790 0 None 1 Cytology of primary site 2 Biopsy of primary site 3 Biopsy or resection of direct extension (including satellite tumors) and/or regional node(s) 4 (3) and (2)5 Resected primary site 6 Resected primary site and regional node(s) 7 Cytology of distant site Biopsy or resection of distant site and/or distant 8 node(s) 9 (7 or 8) with any of (2-4)3 (7 or 8) with (5 or 6)

#### BREAST 740-749. 759 0 None 1 Cytology of primary site Biopsy of primary site (including aspiration biopsy/ 2 frozen section) 3 Biopsy or resection of direct extension and/or regional node(s) 4 (3) and (2)5 Resected primary site Resected primary site and regional node(s) 6 7 Cytology of distant site 8 Biopsy or resection of distant site and/or distant node(s) 9 (7 or 8) with any of (2-4)3 (7 or 8) with (5 or 6) CERVIX UTERI 800-809 0 None 1 Cytology of primary site (Pap smear) 2 Biopsy of primary site, conization, D & C of endocervix only Biopsy or resection of direct extension and/or regional 3 node(s), D & C of endometrium only 4 (3) and (2)5 Resected primary site 6 Resected primary site and regional node(s) 7 Cytology of distant site 8 Biopsy or resection of distant site and/or distant node(s) 9 (7 or 8) with any of (2-4)3 (7 or 8) with (5 or 6)

Note: Removal of tube(s) and/or ovary(ies) is not a diagnostic procedure.

CORPUS UTERI 820-828 0 None Cytology of primary site (Pap smear) 1 2 Biopsy of primary site, D & C Biopsy or resection of direct extension and/or regional 3 node(s). conization 4 (3) and (2)5 Resected primary site 6 Resected primary site and regional node(s) 7 Cytology of distant site Biopsy or resection of distant site and/or distant 8 node(s) 9 (7 or 8) with any of (2-4)(7 or 8) with (5 or 6) 3 Removal of tube(s) and/or ovary(ies) is not a diagnostic pro-Note: cedure. PROSTATE 859 0 None Cytology of primary site (including urinary sediment and/or 1 prostatic fluid after massage) 2 Biopsy of primary site and/or TUR\* 3 Biopsy or resection of direct extension and/or regional node(s) 4 (3) and (2)5 Prostatectomy (excluding TUR) Prostatectomy (excluding TUR) and regional node (s) 6 7 Cytology of distant site Biopsy or resection of distant site and/or distant 8 node(s) 9 (7 or 8) with any of (2-4)(7 or 8) with (5 or 6) 3 \*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.

Note: Orchiectomy is not a diagnostic procedure.

<pre>BLADDER B80-886, 888-889 0 None 1 Cytology of primary site 2 Biopsy or resection of direct extension and/or regional node(s) 4 (3) and (2) 5 Resected primary site and regional node(s) 7 Cytology of distant site 8 Biopsy or resection of distant site and/or distant node(s) 9 (7 or 8) with any of (2-4) 8 (7 or 8) with (5 or 6) *TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy. LIMPH NODES AND LIMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleem) 960-969, 416, 460, 471, 491, 640, 692 Bistology**: 9590 thru 9698, 9750 0 Single nodal site biopsy and/or resections 2 Splemectomy with or without nodal site biopsies and/or resections 3 Bone marrow examination (aspiration and/or biopsy) 4 (3) and (1) 5 (6) and (2) 9 (6) and (2) 9 (6) and (3) 8 (6) and (3) 8 (6) and (4) 8 (6) and (3) 8 (6) and (4) 8 (6) (6) (6) 8 (6) (6) (6) 8 (6) (6) (6) 8 (6) (6) (6) 8 (6) (7) 8 (6) (7) 8 (6) (7) 8 (6) (7) 8 (7) 8</pre>	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	
<ul> <li>Vone</li> <li>Cytology of primary site</li> <li>Biopsy of primary site and/or TUB*</li> <li>Biopsy or resection of direct extension and/or regional node(s)</li> <li>(3) and (2)</li> <li>Besected primary site and regional node(s)</li> <li>Cytology of distant site</li> <li>Biopsy or resection of distant site and/or distant node(s)</li> <li>(7 or 8) with any of (2-4)</li> <li>(7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleem) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 950 thru 9698, 9750 Single nodal site biopsy and/or resections Splemectomy with or without nodal site biopsies and/or resections Bone marrow examination (aspiration and/or biopsy) (3) and (1) (6) and (1) (6) and (1) (3) and (2) </li> </ul>		000-000
<ul> <li>1 Cytology of primary site</li> <li>2 Biopsy of primary site and/or TUR*</li> <li>3 Biopsy or resection of direct extension and/or regional node(s)</li> <li>4 (3) and (2)</li> <li>5 Resected primary site</li> <li>6 Resected primary site and regional node(s)</li> <li>7 Cytology of distant site</li> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resections</li> <li>2 Splemectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> </ul>	880-880,	888-889
<ul> <li>2 Biopsy of primary site and/or TUR*</li> <li>3 Biopsy or resection of direct extension and/or regional node(s)</li> <li>4 (3) and (2)</li> <li>5 Resected primary site and regional node(s)</li> <li>7 Cytology of distant site</li> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>6 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resections</li> <li>2 Splemectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>(3) and (1)</li> <li>(4) and (1)</li> <li>(6) and (2)</li> <li>9 (6) and (2)</li> </ul>	0	None
<ul> <li>3 Biopsy or resection of direct extension and/or regional node(s)</li> <li>4 (3) and (2)</li> <li>5 Resected primary site</li> <li>6 Resected primary site and regional node(s)</li> <li>7 Cytology of distant site</li> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>6 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.</li> <li>LYNPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resections 1 Multiple nodal site biopsies and/or resections</li> <li>2 Splenectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>9 (6) and (3)</li> </ul>	1	Cytology of primary site
<ul> <li>node(s)</li> <li>and (2)</li> <li>Resected primary site</li> <li>Resected primary site and regional node(s)</li> <li>Cytology of distant site</li> <li>Biopsy or resection of distant site and/or distant node(s)</li> <li>(7 or 8) with any of (2-4)</li> <li>(7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>Single nodal site biopsy and/or resections or clinical impression</li> <li>Multiple modal site biopsies and/or resections</li> <li>Splemetomy with or without modal site biopsies and/or resections</li> <li>Go and (1)</li> <li>(6) and (2)</li> <li>(6) and (2)</li> <li>(6) and (3)</li> </ul>		
<ul> <li>5 Resected primary site</li> <li>6 Resected primary site and regional node(s)</li> <li>7 Cytology of distant site</li> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>6 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology*: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple modal site biopsies and/or resections</li> <li>2 Splemectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> </ul>	3	
<ul> <li>6 Resected primary site and regional node(s)</li> <li>7 Cytology of distant site</li> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer-Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeper's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple modal site biopsies and/or resections</li> <li>2 Splenectomy with or without modal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> </ul>	4	(3) and (2)
<ul> <li>7 Cytology of distant site</li> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple modal site biopsies and/or resections</li> <li>2 Splenectomy with or without modal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (2)</li> </ul>	5	Resected primary site
<ul> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 469, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple modal site biopsies and/or resections</li> <li>2 Splemectomy with or without modal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (2)</li> </ul>	6	
<ul> <li>8 Biopsy or resection of distant site and/or distant node(s)</li> <li>9 (7 or 8) with any of (2-4)</li> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 469, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple modal site biopsies and/or resections</li> <li>2 Splemectomy with or without modal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (2)</li> </ul>	7	Cytology of distant site
<ul> <li>9 (7 or 8) with any of (2-4)</li> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple nodal site biopsies and/or resections</li> <li>2 Splenectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (3)</li> </ul>		Biopsy or resection of distant site and/or distant
<ul> <li>8 (7 or 8) with (5 or 6)</li> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple nodal site biopsies and/or resections</li> <li>2 Splemectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (3)</li> </ul>	٥	
<ul> <li>*TUR is to be coded as treatment in Field 22, First Course of Cancer- Directed Therapy.</li> <li>LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 469, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750</li> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple nodal site biopsies and/or resections</li> <li>2 Splenectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (3)</li> </ul>	,	(rot of when any of (2-4)
Directed Therapy. LYMPH NODES AND LYMPHOID TISSUE (Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 460, 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750  0 Single nodal site biopsy and/or resection or clinical impression  1 Multiple nodal site biopsies and/or resections  2 Splenectomy with or without nodal site biopsies and/or resections  3 Bone marrow examination (aspiration and/or biopsy)  4 (3) and (1)  5 (3) and (2)  6 Liver biopsy  7 (6) and (1)  8 (6) and (2)  9 (6) and (3)	3	(7 or 8) with (5 or 6)
<pre>(Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 46), 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750 0 Single nodal site biopsy and/or resection or clinical impression 1 Multiple modal site biopsies and/or resections 2 Splenectomy with or without nodal site biopsies and/or resections 3 Bone marrow examination (aspiration and/or biopsy) 4 (3) and (1) 5 (3) and (2) 6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)</pre>		
<pre>(Including Waldeyer's ring, thymus, and and spleen) 960-969, 416, 46), 471, 491, 640, 692 Histology**: 9590 thru 9698, 9750 0 Single nodal site biopsy and/or resection or clinical impression 1 Multiple modal site biopsies and/or resections 2 Splenectomy with or without modal site biopsies and/or resections 3 Bone marrow examination (aspiration and/or biopsy) 4 (3) and (1) 5 (3) and (2) 6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)</pre>	LYMPH NODE:	S AND LYMPHOID TISSUE
Histology**: 9590 thru 9698, 9750 O Single nodal site biopsy and/or resection or clinical impression 1 Multiple nodal site biopsies and/or resections 2 Splenectomy with or without nodal site biopsies and/or resections 3 Bone marrow examination (aspiration and/or biopsy) 4 (3) and (1) 5 (3) and (2) 6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)	(Includia	ng Waldeyer's ring, thymus, and
<ul> <li>0 Single nodal site biopsy and/or resection or clinical impression</li> <li>1 Multiple nodal site biopsies and/or resections</li> <li>2 Splenectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (3)</li> </ul>		
<pre>impression 1 Multiple nodal site biopsies and/or resections 2 Splenectomy with or without nodal site biopsies and/or resections 3 Bone marrow examination (aspiration and/or biopsy) 4 (3) and (1) 5 (3) and (2) 6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)</pre>	HISTOLOG	Y**: 9590 thru 9698, 9750
<ul> <li>2 Splenectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (3)</li> </ul>	0	• • • •
<ul> <li>2 Splenectomy with or without nodal site biopsies and/or resections</li> <li>3 Bone marrow examination (aspiration and/or biopsy)</li> <li>4 (3) and (1)</li> <li>5 (3) and (2)</li> <li>6 Liver biopsy</li> <li>7 (6) and (1)</li> <li>8 (6) and (2)</li> <li>9 (6) and (3)</li> </ul>	1	Nultiple modal site biopsies and/or resections
<ul> <li>Bone marrow examination (aspiration and/or biopsy)</li> <li>(3) and (1)</li> <li>(3) and (2)</li> <li>Liver biopsy</li> <li>(6) and (1)</li> <li>(6) and (2)</li> <li>(6) and (3)</li> </ul>		
4 (3) and (1) 5 (3) and (2) 6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)		resections
5 (3) and (2) 6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)	3	Bone marrow examination (aspiration and/or biopsy)
6 Liver biopsy 7 (6) and (1) 8 (6) and (2) 9 (6) and (3)		
7 (6) and (1) 8 (6) and (2) 9 (6) and (3)	5	(3) and (2)
8 (6) and (2) 9 (6) and (3)	6	
9 (6) and (3)	•	
5 LD) 30(1 LA)		
- (6) and (5)	5 -	
(v) and (J)	-	

\*\*Includes lymphoma (nodular, diffuse, and follicular), reticulosarcomas, and Hodgkin's disease

Code:

0 One primary only

1 First of two or more primaries

2 Second of two or more primaries

3 Third of three or more primaries

4 Fourth of four or more primaries

5 Fifth of five or more primaries

6 Sixth of six or more primaries

7 Seventh of seven or more primaries

8 Eighth or later primary

9 Unspecified sequence number

Specific:

Sequence Number, Field 14, codes the chronological appearance of all primary malignant and/or in-situ tumors as defined on page vi of this manual. Even if the first primary tumor was experienced by the patient before becoming a resident of the area covered or prior to the date each participant entered the SEER Program, it would be considered as sequence number "1" if later primaries are known to the SEER participant.

If two or more independent primaries are diagnosed simultaneously, the lowest sequence number will be assigned to the diagnosis with the worst prognosis. This means consideration of stage or extent of disease and also the grade or degree of malignancy. Therefore, look first at the difference in EOD, then give priority to the diagnosis with the highest terminal digit (omitting 6 and 9) in the histology code (Field 18). If no difference in prognosis is evident, the decision must be arbitrary.

Determination of Primary Tumors, Operational Rules:

The discussion above is secondary to a determination of how many primary tumors the patient has. The rules given on page vii of this manual are used to make this determination. Sequence number can then be assigned accordingly.

\*\*\*\*\*\*

#### Code:

CP 40-42 From the International Classification of Diseases for Oncology (ICD-0), Topography, Numerical List (see below)

CP 43 Blank

Specific:

The Topography section of the International Classification of Diseases for Oncology (ICD-O) is used for coding the Primary Site of all tumors reported to SEER. For all site codes in ICD-O, the SEER Program drops the first digit, "1", and the decimal point.

In ICD-O, site codes may be found in the Topography, Numerical List, section (pp. 1-19) or in the Alphabetic Index (pp. 47-128) which includes both Topography and Morphology terms. In the Alphabetic Index all site (Topography) codes are indicated by a "T-" preceding the code number. The "T-" should not be coded.

Example: A patient's record states the primary site is "cardia of stomach". This site is looked up in the Alphabetic Index, either under "cardia" or "stomach" and is found to be T-151.0. In coding for SEER, drop the T-, the first 1, and the decimal point; then enter the three-digit code, 510, in CP 40-42.

DEFINITIONS

Primary vs Secondary:

The major emphasis within the SEER Program is that the primary site be identified and NOT a metastatic site. If the site of origin cannot be determined exactly, it may be possible to use the NOS category of an organ system or the Ill-Defined Sites codes (950-958) (see p. ix of ICD-0) instead of code 999 which denotes a completely unknown site. However, it is proper to code 999 in CP 40-42 if the only information available pertains to a secondary site.

Where the record is not entirely explicit, it is suggested that a physician determine whether the cancer site is primary or secondary and which Topography code would be the most definitive one to use.

Code a lymphoma to an extra-nodal site when there is no nodal involvement of any kind or there is a medical statement that the origin was in an extra-nodal site. Field 15 CP 40-43

#### \_\_\_\_\_\_

In the Introduction of ICD-0 (p. xvii) the topic of "Site-Specific Morphology" terms is discussed. If the patient record has a morphologic term with a T number listed in ICD-0, use this T number if no definite site is given or if only a metastatic site is given. For example, if the diagnosis is Hepatoma (M-8170/3) with no other statement about topography, code to primary site T-155.0 (liver) as this morphology is always indicative of a primary malignancy in the liver.

#### Multiple Sub-sites:

Each three-digit site of colon (530-537), rectum (540-541), bone (700-708), connective tissue (710-717), and skin (730-737) is considered to be a major primary site (Definition, p. vii) whereas all other three-digit site codes are considered to be subsites of a major twodigit site. For example 741, upper-inner quadrant of the breast, is considered to be a subsite of female breast, 74\_. The rules on pages vii and viii should be used in determining the number of primary cancers to be reported and the appropriate site code for each.

Field 16 describes this primary site only and should be coded for each primary independently.

Code:

- 0 Not a paired site
- 1 Right: origin of primary
- 2 Left: origin of primary
- 3 Only one side involved, right or left origin unspecified
- 4 Bilateral involvement, lateral origin unknown: stated to be single primary
- Paired site, but no information concerning laterality 9

Specific:

Laterality codes of 1-9 must be used for the following sites except as noted. Only major headings are listed. However, laterality should be coded for all subheadings included in ICD-O unless specifically excluded. Such exclusions must be coded "0".

420 Parotid gland
421 Submandibular gland
422 Sublingual gland
460 Tonsil, NOS
461 Tonsillar fossa
462 Tonsillar pillar
600 Nasal cavity (excluding Nasal cartilage, Nasal septum)
601 Niddle ear
602 Haxillary sinus
604 Frontal sinus
622 Main bronchus (excluding Carina)
623 Upper lobe, lung
624 Niddle lobe, lung
625 Lower lobe, lung
628 Other parts of lung or bronchus
629 Lung, NOS
630-639 Pleura
703 Rib, Clavicle (excluding Sternum)
704 Long bones of upper limb, Scapula
705 Short bones of upper limb
706 Pelvic Bones (excluding Sacrum, Coccyx, & Symphysis pubis)
707 Long bones of lower limb
708 Short bones of lower limb
(continued)

~~~~~~~~~	
712	Connective, Subcutaneous, and other Soft tissues of upper
	limb and shoulder
713	Connective, Subcutaneous, and other Soft tissues of lover limb and hip
731	Skin of eyelid
732	
733	
735	
	Skin of arm and shoulder
737	
740-74	9 Female breast
759	Male breast
830	Ovary
832	Fallopian tube
860	Undescended testis
869	Testis, NOS
875	Epididymis
876	Spermatic cord
890	Kidney, NOS
891	Renal pelvis
892	Øreter
900-90	
940	Suprarenal gland
945	
740	Carotid body

Note: Laterality may be submitted for sites other than those required above.

۰.

A blank should be submitted in this field.

The histologic type is a six-digit code. It consists of three parts:

- CP 46-49 The 4-digit histologic type of ICD-0 Morphology Section
- CP 50 The Behavior code for Neoplasms of ICD-0 (See p. 20 of ICD-0.)
- CP 51 The Grading or Differentiation code of ICD-0 (See p. 20 of ICD-0.)

The Morphology Section of the International Classification of Diseases for Oncology (ICD-O) published by the World Health Organization is to be used for coding all histologic types of tumors reported to SEER. The first four digits before a slash (/) are Histologic Type followed by the Behavior code in the fifth digit and the Grading or Differentiation code in the sixth digit.

# Histologic Type

In coding histology, all pathology reports for the case for a particular site should be used. Although the material from the most representative tissue is usually the best, sometimes all of the positive material may be removed at biopsy. For example:

> Skin biopsy: Superficial malignant melanoma Wide excision: No residual tumor

This should be coded Superficial malignant melanoma (872039).

Sometimes more detail is found in the microscopic description than in the final pathologic diagnosis; for example, the microscopic description may say the tumor is "mucin-producing", "papillary", or keratinizing", but the final pathologic diagnosis may read only "carcinoma" or "adenocarcinoma". Do not modify the final pathologic diagnosis to pick up specific terms such as "mucinproducing". Code only the final pathologic diagnosis.

Do not use the ICD-O histology code M-9990, "no microscopic confirmation, clinically maligmant tumor". Use code 8000 for terms such as "malignant tumor", "malignant neoplasm", or "cancer". If the physician is more specific, use the more specific histology code. Field 19, Diagnostic Confirmation, will indicate whether or not the diagnosis was microscopically confirmed. -----

# Behavior Code

Only tumors ending in the Behavior code /2 (in-situ) or /3 (malignant) are to be reported to SEER. All neoplasms are listed in both the numeric and alphabetic indices of ICD-0 with their usual behavior code. However, as explained on pages xiv and xv of the ICD-O Introduction, if a pathologist calls a tumor in-situ (/2) or malignant (/3) which is not listed as such in ICD-O, the appropriate behavior code is to be coded and reported to SEER. For example, see Table 1 in ICD-O. An edit review of all such cases will take place unless a "1" is coded in CP 95. SEER does not accept tumors with behavior codes /0, /1, /6, or /9. If the only specimen on which the histologic diagnosis is made was from a metastatic site, code the histologic type of the metastatic site with a /3 for the behavior code. Assume the primary site had the same histology as the metastatic site.

For the purposes of this program, the meaning of "different histologies" refers to a difference in the first three digits of the histology code. However, the Behavior code (fifth digit) should always be taken into consideration. In the event there are two histologies in the same lesion, code the highest histologic number if no combined histology code exists. If the Behavior code is the SAME, code the higher histology code. For example:

Biopsy: Squamous cell carcinoma of cervix (807039) Α. Surgery: Squamous cell carcinoma, keratinizing type, of cervix (807139)

This should be coded to the highest morphology (807139).

B. Path report: Mixed adenocarcinoma and squamous cell carcinoma of cervix

This should be coded to the combination code for Adenosquamous carcinoma (856039).

C. Path report: Transitional cell epidermoid carcinoma

"Transitional cell carcinoma, NOS" has a code of M-8120/39 in ICD-0 and "Epidermoid carcinoma, NOS" has a code of M-8070/39. Code this case to the higher code (812039). (See further discussions in ICD-0, p. xviii.)

If the Behavior code is NOT THE SAME, select the morphology code of the higher Behavior code (the invasive tumor). For example:

> Report 1: Invasive carcinoma of cervix (801039) Report 2: Squamous cell carcinoma in-situ of cervix (807029)

This should be coded to the report of the invasive tumor (801039).

#### \*\*\*\*

Note that "in-situ" is a concept based upon histologic evidence. Therefore, clinical evidence alone cannot justify the usage of this term. In addition, any pathological diagnosis qualified as "microinvasive" is not acceptable as "carcinoma in-situ"; such a diagnosis must be coded to one of the "localized" categories.

Grading or Differentiation Code

The grading or differentiation code is to be placed in CP 51 of Field 18 and can be found on page 20 of ICD-0.

If a diagnosis indicates two different degrees of grade or differentiation (e.g., "well and poorly differentiated" or "grade II-III"), code to the higher grade code (Rule 10, p. xxiii in ICD-0).

If the final pathologic diagnosis indicates a degree of differentiation or grade different from the microscopic diagnosis, code the final pathologic diagnosis since this is the most representative diagnosis. For example:

Micro: Moderately differentiated squamous cell carcinoma with poorly differentiated areas Final: Moderately differentiated squamous cell carcinoma

Code to the final diagnosis: Moderately differentiated (807032).

Usually there will be no statement as to grade for in-situ lesions. However, if a grade is stated, it should be coded.

When there is variation in the usual terms for degree of differentiation, code to the highest grade as specified below:

Term	Grade	Code
Low grade	I-II	2
Medium grade	II-III	3
High grade	III-IV	4
Partially well differentiated	<b>I-II</b>	2
Moderately undifferentiated	III	3
Relatively undifferentiated	III	3

Field 19 indicates whether AT ANY TIME during the patient's medical history there was microscopic confirmation of the malignancy of this cancer. Field 19 indicates not only the fact of microscopic confirmation, but the nature of the best evidence available. Thus, this is a priority series with code 1 taking precedence. Each number takes priority over all higher numbers.

#### Code:

Microscopic Proof

- 1 Positive histology
- 2 Positive exfoliative cytology, no positive histology
- 4 Positive microscopic confirmation, method not specified

Not Microscopically Confirmed

- 6 Direct visualization without microscopic confirmation
- 7 Radiography without microscopic confirmation
- 8 Clinical diagnosis only
- 9 Unknown whether or not microscopically confirmed

#### Specific:

Code 1: Microscopic diagnoses based upon specimens from biopsy, frozen section, surgery, autopsy, or D and C. Positive hematologic findings relative to leukemia are also included. Bone marrow specimens (including aspiration biopsies) are coded as "1".

Code 2: Cytologic diagnoses based on microscopic examination of cells as contrasted with tissues. Included are smears from sputum, bronchial brushings, bronchial washings, tracheal washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, and urinary sediment. Cervical and vaginal smears are common examples. Also included in code 2 are diagnoses based upon paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.

Code 4: Cases which are stated to be microscopically confirmed but with no detailed information on method.

Code 6: Visualization includes diagnosis made at surgical exploration or by use of the various endoscopes (including colposcope, mediastinoperitonecscope). However, use code 6 only if such visualization is not supplemented by positive histology or positive cytology reports. Code 6 is also used when gross autopsy findings were the only positive information. Field 19 CP 52

Code 7: Cases with diagnostic radiology for which there is not also a positive histology or a positive cytology report. This will include all "scans" not also microscopically confirmed.

Code 8: Cases diagnosed by clinical methods not mentioned above and for which there were no positive microscopic findings.

Code 9: Cases for which the method of confirmation is unknown. "Death Certificate Only" cases are coded "9".

General:

Note that, since Field 19 covers the patient's ENTIRE medical history, follow-up information may change the coding in this field for any case not coded "1".

#### \*\*\*\*\*\*\*\*\*

There are three extent of disease schemes:

- **A** Non-specific
- B Two-digit site-specific
- C Expanded (13-digit) site-specific

The format for each of these schemes is presented after the following table:

### TABLE: Appropriate EOD Code

This table, given in primary site code order, specifies which EOD scheme is required and where the EOD codes are located for a particular site.

Exception to this table: If a case is reported via "Death Certificate Only", use the Non-specific scheme and code "--" (unstaged) in CP 67-68.

400       B       Buff pages         401       B       Buff pages         403       B       Buff pages         404       B       Buff pages         405       A       ii         406       B       Buff pages         405       A       ii         406       B       Buff pages         408       A       ii         409       A       ii         410       B       Buff pages         411-414       B       Buff pages         415       A       ii         410       B       Buff pages         411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (ercl. hist 959-969,975)       B       Buff pages         413       A       ii       ii         420       B       Buff pages       411         420       B       Buff pages       422         421       B       Buff pages         422       A       ii       ii         430       B       Buff pages       431	Primary Site Code	EOD Scheme Required	Page(s) in EOD Manual*
403BBuff pages $404$ BBuff pages $405$ Aii $406$ BBuff pages $408$ Aii $409$ Aii $410$ BBuff pages $411-414$ BBuff pages $415$ Aii $416$ (hist 959-969,975)C74-77 $416$ (excl. hist 959-969,975)BBuff pages $419$ Aii $420$ BBuff pages $421$ BBuff pages $422$ Aii $428$ Aii $430$ BBuff pages $431$ BBuff pages $433$ Aii $439$ Aii $449$ BBuff pages $450, 451$ BBuff pages $452, 454$ BBuff pages			Buff pages
404       B       Buff pages         405       A       ii         406       B       Buff pages         408       A       ii         409       A       ii         409       A       ii         410       B       Buff pages         411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (excl. hist 959-969,975)       B       Buff pages         418       A       ii       ii         419       A       ii       ii         420       B       Buff pages       421         420       B       Buff pages       422         421       B       Buff pages         422       A       ii       ii         428       A       ii       ii         429       A       iii       ii         430       B       Buff pages       431         439       A       ii       ii         439       A       ii       ii         439       A       ii       ii			Buff pages
405       A       ii         406       B       Buff pages         408       A       ii         409       A       ii         410       B       Buff pages         410       B       Buff pages         411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (excl. hist 959-969,975)       B       Buff pages         418       A       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         452 </td <td></td> <td></td> <td>Buff pages</td>			Buff pages
406       B       Buff pages         408       A       ii         409       A       ii         410       B       Buff pages         411-414       B       Buff pages         411-414       B       Buff pages         411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (excl. hist 959-969,975)       B       Buff pages         418       ii       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452,52       B       Buff pages         453,454       B       Buff pages			
408       A       ii         409       A       ii         410       B       Buff pages         411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (excl. hist 959-969,975)       B       Buff pages         418       A       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			
408       A       ii         409       A       ii         410       B       Buff pages         411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (excl. hist 959-969,975)       B       Buff pages         418       A       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages		В	Buff pages
410BBuff pages411-414BBuff pages415Aii416 (hist 959-969,975)C74-77416 (excl. hist 959-969,975)BBuff pages418Aii419Aii420BBuff pages421BBuff pages422Aii428Aii429Aii430BBuff pages431BBuff pages433Aii439Aii440-449BBuff pages450,451BBuff pages452BBuff pages453,454BBuff pages		λ	ii
411-414       B       Buff pages         415       A       ii         416       (hist 959-969,975)       C       74-77         416       (excl. hist 959-969,975)       B       Buff pages         418       ii       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       iii         429       A       iii         430       B       Buff pages         431       B       Buff pages         433       A       iii         439       A       iii         440-449       B       Buff pages         452       B       Buff pages         452       B       Buff pages			
415       A       ii         416 (hist 959-969,975)       C       74-77         416 (excl. hist 959-969,975)       B       Buff pages         418       ii       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages			Buff pages
415       A       ii         416 (bist 959-969,975)       C       74-77         416 (excl. hist 959-969,975)       B       Buff pages         418       A       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages			Buff pages
416 (excl. hist 959-969,975)       B       Buff pages         418       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			ii
418       ii         419       A       ii         420       B       Buff pages         421       B       Buff pages         422       A       ii         428       A       iii         429       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         430       B       Buff pages         431       B       Buff pages         433       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			
419Aii420BBuff pages421BBuff pages422Aii428Aiii429Aii430BBuff pages431BBuff pages438Aii439Aii440-449BBuff pages450,451BBuff pages452BBuff pages453,454BBuff pages			
420BBuff pages421BBuff pages422Aii428Aiii429Aii430BBuff pages431BBuff pages438Aii439Aii440-449BBuff pages450,451BBuff pages452BBuff pages453,454BBuff pages			
421       B       Buff pages         422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         438       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			
422       A       ii         428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         438       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			Buff pages
428       A       ii         429       A       ii         430       B       Buff pages         431       B       Buff pages         438       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			Buff pages
429Aii430BBuff pages431BBuff pages431BBuff pages438Aii439Aii440-449BBuff pages450,451BBuff pages452BBuff pages453,454BBuff pages			
430BBuff pages431BBuff pages438Aii439Aii440-449BBuff pages450,451BBuff pages452BBuff pages453,454BBuff pages			
431       B       Buff pages         438       A       ii         439       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			
438       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			Buff pages
438       A       ii         439       A       ii         440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			Buff pages
440-449       B       Buff pages         450,451       B       Buff pages         452       B       Buff pages         453,454       B       Buff pages			ii
450,451         B         Buff pages           452         B         Buff pages           453,454         B         Buff pages	439		
450,451         B         Buff pages           452         B         Buff pages           453,454         B         Buff pages			Buff pages
452BBuff pages453,454BBuff pages			Buff pages
453,454 B Buff pages	452		Buff pages
455 A ii		В	Buff pages
	455	λ	ii

TABLE: Appropriate	EOD C	Code	(continued)
--------------------	-------	------	-------------

Primary Site Code	EOD Scheme Required	Page(s) in EOD Manual*
456 458	B A	Buff pages ii
459	A	ii
460 (hist 959-969,975)	С	74-77
460 (excl hist 959-969,975)	В	Buff pages
461-469	В	Buff pages
470	В	Buff pages
471 (hist 959-969,975)	С	74-77
471 (excl hist 959-969,975)	B	Buff pages
472-479	B	Buff pages
480-489	В	Buffpages
49) 491 (hist 959-969,975)	A	ii 74 77
491 (mist 959-969,975) 491 (excl hist 959-969,975)	C A	74-77 ii
498	λ	11 ii
499	À	11 11
500-505	B	Buff pages
508	Å	ii
509	Ä	ii
510 (cardia only)	Ĉ	8-11
510 (excluding cardia)	Â	ii
511-519	C	8-11
520	В	Buff pages
521	В	Buff pages
522	В	Buff pages
523	A	iİ
528	A	ii
529	- <b>A</b>	ii
530, 531	С	20-23
532	С	24-27
533	C	28-31
534	С	12-15
535	λ	ii
536	C	16-19
537	C	20-23
538	Å	ii
539	λ	ii
540	С	32-35

•

. ..

# TABLE: Appropriate EOD Code (continued)

Primary	EOD Scheme	Page(s) in
Site Code	Required	EOD Manual*
541 542-543 548 550-551 560 561-562 568 569	C B A B B B A A A	36-39 Buff pages ii Buff pages Buff pages Buff pages ii ii
570	B	Buff pages
571-572	B	Buff pages
573	A	ii
574	A	ii
578	A	ii
579	A	ii
580	A	ii
588	A	ii
589	A	ii
590	A	ii
598	A	ii
599	A	ii
600-605,608,609	A	ii
613	B	Buff pages
611	B	Buff pages
612	B	Buff pages
613	A	ii
618 619 620 622 (carina only) 622-629 (excluding carina)	A A A C	ii ii ii 40-45
633 631 638 639 640 (hist 959-969,975) 640 (excl hist 959-969,975)	A A A C A	ii ii ii 74-77 ii
641-643,648,649	A	ii

TABLE: Appropriate EOD Code (continued)

Primary Site Code	EOD Scheme Required	Page(s) in EOD Manual*
650,658,659	A	ii
690 <b>-</b> 69 <b>1</b>	λ	ii
692 (hist 959-969,975) `	С	74-77
692 (excl hist 959-969,975)	A	ii
693	A	ii
699	A	ii
700-709	В	Buff pages
71), 712-719	A	ii
730-737 (hist 872-879)	C	46-49
730-737 (excl hist 872-879)	В	Buff pages
738	A	ii
739	A	ii
740-749,759	С	50-54
799	λ	ii
80)-809	C	55-59
819 820-828	A	ii
830	C	60-64
832	B	Buff pages
833	В	Buff pages
834	A	ii
835	A	ii
838	A	ii
839	A	ii
840	<u>А</u> В	ii
841-844 (hist 872-879)	В С	Buff pages
841-844 (mist 872-879) 841-844 (excl hist 872-879)	B	46-49
848	۵ ۸	Buff pages
849	A	ii ii
859	R C	—
860,869	B	65-69 Buff accor
871,872,874 (hist 872-879)	C	Buff pages
871,872,874 (mist 872-879) 871,872,874 (excl hist 872-8		46-49 Buff pages
873	/9) B A	Buff pages
875	A A	ii ii
876	A	11 ii
070	A	11

# TABLE: Appropriate EOD Code (continued)

Primary Site Code	EOD Scheme Required	Page(s) in EOD Manual*
877 (hist 872-879)	С	46-49
877 (excl hist 872-879)	λ	ii
878	A	ii
879	A	ii
880-886	С	70-73
887	λ	ii
888,889	С	70-73
890	В	Buff pages
891,892	В	Buff pages
893	A	ii
894	λ	ii
898	A	ii
899	A	ii
90 )- 9 )9	A	ii
910-919	A	ii
921-923,928,929	A	ii
939	В	Buff pages
947,941,943-946,948,949	A	ii
950-955,958	A	ii
960-969 (hist 959-969,975)	С	74-77
96)-969 (excl hist 959-969,9	75) A	ii
999	A	ii
****		***

\*

This column refers to pages or sections of the SEER Program manual Extent of Disease - Codes and Coding Instructions, April, 1977.

The three Extent of Disease schemes are coded according to the following general format:

		CP	Description
A	Non-Specific EOD	53-66	Blank
	scheme:	67-68	Non-specific code
В	Two-digit Site-Specific	53-66	Blank
	EOD scheme:	67-68	Two-digit code
С	Expanded Site-Specific	53-54	Tumor size
	EOD scheme:	55	Blank
		<b>56-5</b> 9	Direct extension of primary tumor
		60	Site-specific information
		61-62	Regional lymph node involvement
		63-64	Distant lymph node involvement
		65	Distant site involvement
		66-68	Blank

### Discussion:

Extent of Disease should be limited to all information available by the end of the first hospitalization for surgical resection if done within two months of diagnosis or two months after diagnosis for all other cases, both treated and untreated.

If a patient has radiation therapy followed by definitive surgery within two months of diagnosis, include all information available through definitive surgery in determining the Oper/Path assessment of extent of disease. The separate clinical evaluation will be limited to procedures up to the initiation of definitive therapy.

If an excisional biopsy, D and C, cone biopsy, lymphadenectomy, TUR (prostate or bladder), or a polypectomy is followed by further definitive therapy within two months of diagnosis, include all information available through the definitive surgery in determining extent of disease.

For "Death Certificate Only" cases, code "--" in the Non-Specific code.

For non-specific codes only, use page 1 of the SEER Summary Staging Guide, April 1977, for a description of summary definitions.

This is a four-digit field representing the date of initiation of the patient's first cancer-directed treatment for this cancer. The first two digits indicate the month; the last two digits identify the year.

Code:

Code 0000 if there was no cancer-directed therapy. Otherwise:

- CP 69-70 Month
  - 01 January 02 February 03 March 04 April 05 May 06 June 07 July 08 August 09 September 10 October 11 November 12 December 99 Unknown
- CP 71-72 Year

Last two digits of year

99 Unknown

#### General:

The date of admission for that hospitalization during which the first cancer-directed therapy was begun is an acceptable entry in Field 21. If cancer-directed treatment was first received on an outpatient basis, code the date (month/year) that cancer directed-therapy was started. Should there be a case with unknown year of cancer-directed therapy, the entire field should be coded 9999.

When an unproven therapy (e.g., laetrile) is the first course of therapy, the date the patient started taking that therapy is the date therapy was initiated.

Field 22 CP 73-79

\*\*\*\*\* CP Code 73 Surgery ) None 1 Surgical Resection 8 Surgery recommended, unknown if performed 9 Unknown 74 Radiation 0 None 1 Beam Radiation 2 Other Radiation 3 Combination of 1 and 2 7 Radiation, NOS - method or source not specified 8 Radiation recommended, unknown if administered 9 Unknown 75 Radiation Sequence with Surgery If treatment consisted of both surgery and radiation, i.e., CP 73 = 1 AND CP 74 = 1, 2, 3 or 7, code: 2 Radiation before surgery Radiation after surgery 3 4 Radiation both before and after surgery 9 Sequence unknown, but both were given All other cases, code: 0 Not applicable - This includes the following combinations of CP 73 and CP 74: CP 73 CP 74 0,8,9 0-9 0,8,9 76 Chemotherapy 0 None 1 Chemotherapy 8 Chemotherapy recommended, unknown if administered 9 Unknown 77 Hormonal Therapy 0 None 1 Hormones (including NOS) Endocrine Surgery (if cancer is of another site) 2 Combination of 1 and 2 3 4 Endocrine Radiation (if cancer is of another site) 5 Combination of 1 and 4 Combination of 2 and 4 6 Combination of 1 and 2 and 4 7 8 Hormonal therapy recommended, unknown if administered 9 Unknown

		*****
СР	Code	
78		Immunotherapy
• •	0	None
	1	Immunotherapy
	8	Immunotherapy recommended, unknown if administered
	9	Unknown
<b>7</b> 9		Other Cancer-Directed Therapy
	0	None (No cancer-directed therapy except as coded in CP 73-78)
•	1	Other cancer-directed therapy (including dermoplaning, hyperbaric oxygen as adjunct, etc.)
	2	Experimental cancer-directed therapy (not included in CP 73-78)
	3	Double-blind study, code not yet broken
	7	Unproven therapy (including laetrile, krebiozen, etc.)
	8	Other cancer-directed therapy recommended, unknown if administered

9 Unknown

For the SEER Program the concept of definitive treatment is limited to procedures directed toward cancer tissues whether of the primary site or metastases. If a specific therapy normally affects, controls, changes, removes, or destroys cancer tissue, it is classified as definitive treatment even if it cannot be considered curative for a particular patient in view of the extent of disease, incompleteness of treatment, lack of apparent response, size of dose, operative mortality, or other criteria.

DEFINITION OF "FIRST COURSE" FOR ALL MALIGNANCIES EXCEPT LEUKEMIAS

- For all cases, the first course of therapy includes cancerdirected treatment received by the patient within the first four months of initiation of therapy. All modalities of treatment are included regardless of sequence or the degree of completion of any component method.
- 2. EXCEPTION: Should there be a change in therapy due to apparent failure of the original planned and administered treatment or because of progression of the disease, such therapy should be excluded from the first course and considered part of a second course of therapy.

DEFINITIONS OF "FIRST COURSE" FOR LEUKEMIAS

The basic time period is two months after the date of initiation of therapy. When precise information permits, the first course of definitive treatment is to be related to the first "remission" as follows - even in violation of the two-month rule:

- A. If a remission complete or partial is achieved during the first chemotherapeutic attack upon the leukemic process, include:
  - 1. All definitive therapy considered as "remission inducing" for the first remission, and
  - 2. All definitive therapy considered as "remission maintaining" for the first remission, i.e., irradiation to the central nervous system.
- B. Disregard all treatment received by the patient after the lapse of the first remission.
- C. If no remission is attained during the first course of chemotherapy, use the two-month rule.

# DEFINITIONS OF CANCER-DIRECTED THERAPY

"Cancer tissue" means proliferating malignant cells or an area of active production of malignant cells. In some instances, malignant cells are found in tissues in which they did not originate and in which they do not reproduce. A procedure removing malignant cells but not attacking a site of proliferation of such cells is NOT to be considered cancer treatment for the purpose of this program.

The definition includes only cancer-directed definitive therapy and excludes therapy which treats the patient but has no effect on malignant tissue. Treatment solely for the relief of symptoms is therefore excluded.

The term "palliative" is normally used in two senses: (a) as meaning non-curative and (b) as meaning the alleviation of symptoms. Thus, some of the treatments termed palliative fall within the definition of cancer-directed treatment and some are excluded as treating the patient but not the cancer.

SURGERY (CP 73): The removal of cancer tissue by operative procedures. Included are: Local Excision with removal of cancer tissue (including excisional biopsy and excluding incisional biopsy) Hysterectomy for uterine cancer Mastectomy for breast cancer Gastrectomy for stomach cancer TUR (transurethral resection) with removal of cancer tissue for bladder and prostate neoplasms Dessication and Curettage for bladder and skin neoplasms Fulguration for bladder, skin and rectum neoplasms Electrocautery Photocoagulation Cryosurgery Chemosurgery (Moh's technique) Conization for carcinoma in-situ of the cervix uteri Dilatation and Curettage for carcinoma in-situ of the cervix uteri or carcinoma in-situ of the corpus uteri Surgery removing metastatic malignant tissue Laser therapy RADIATION (CP 74): Beam Radiation (code "1") directed to cancer tissue regardless of source of radiation. Included is treatment via: X-ray Cobalt Linear accelerator Neutron beam Betatron Spray radiation Radiation other than Beam Radiation directed to cancer tissue. Included is treatment via: Internal use of radioactive isotopes whether given orally, intracavitarily, interstitially, or by intravenous injection. All implants, molds, seeds, needles, applicators of radioactive material such as radium, radon, radioactive gold, etc. RADIATION SEQUENCE WITH SURGERY (CP 75): See page 22.1 of this manual.

\*\*\*\*\*

## CHEMOTHERAPY (CP 76):

Any chemical which is administered to attack or treat cancer tissue and which is not considered to achieve its effect through change of the hormone balance. Only the agent, not the method of administration of the drug, is to be considered in coding.

ENDOCRINE (HORMONE/STEROID) THERAPY (CP 77):

The use (primary or secondary) of any type of therapy which exercises its effect on cancer tissue via change of the hormone balance of the patient. Included are the administration of hormones, anti-hormones, or steroids, surgery for hormonal effect on cancer tissue, and radiation for hormonal effect on cancer tissue.

Specifically:

Hormones and anti-hormones (cancer-directed only) - are to be coded for all sites (primary and metastatic).

Adrenocorticotrophic hormones (cancer-directed only) - are to be coded for leukemias, lymphomas, and multiple myeloma.

Endocrine surgery - is to be coded for breast and prostate only:

Oophorectomy (breast) Orchiectomy (prostate) Adrenalectomy Hypophysectomy

Both glands or the remaining gland of paired glands must be removed for the procedure to be considered endocrine surgery.

Endocrine radiation - is to be coded for breast and prostate only. The same rules apply as for endocrine surgery.

IMMUNOTHERAPY (CP 78):

Administration of antigen or antibody plus any technique which heightens the patient's immune response. Used almost always as an adjunct to surgery, radiation, and/or chemotherapy. Examples are:

> Virus therapy B.C.G. Vaccine therapy Bone marrow transplant

Field 22 CP 73-79

OTHER CANCER-DIRECTED THERAPY (CP 79):

Any and all cancer-directed therapy that is not appropriately assigned to the other specific treatment codes, including an experimental or newly developed method of treatment differing greatly from proven types of cancer therapy. Examples are:

> Dermoplaning or wire brush surgery (multiple skin cancer) Hyperbaric oxygen (as adjunct to definitive treatment) Hyperthermia

Double-Blind Clinical Trial information: After the code is broken, code Field 22 according to the treatment actually administered.

NO CANCER-DIRECTED THERAPY (CP 73-79):

If patient receives only symptomatic or supportive therapy this is classified as "no cancer-directed therapy". Field 22 would be coded as 0000000 for such a case.

A blank should be submitted in this field.

\*\*\*\*\*\*\*\*\*\*\*

Field 24 indicates the date of last follow-up or the date of death. The first two digits indicate the appropriate month and the last two digits identify the year. This field pertains to the date of the actual information and not the date the follow-up inquiry was forwarded or the date the follow-up report was received.

Code:

- Month CP 81-82
  - 01 January 02 February 03 March 04 April 05 May 06 June 07 July 08 August 09 September 10 October 11 November 12 December 99 Unknown
- CP 83-84 Year

Last two digits of the year of last follow-up or death.

There should be NO use of code for unknown year, Note: "99", in this field.

General:

If there is no new follow-up information, the entry in Field 24 is the same as that of the previous follow-up for this patient. If no follow-up information is ever received, code the date of first hospital discharge.

Remember, this field pertains to the patient and not to the cancer. Thus, for a patient with more than one malignancy, all records for that patient should have the same code in Field 24.

Field 25 summarizes the best available information concerning the vital and cancer status of the patient as of the date of last followup or death. Detailed information from autopsies, when available, should be used in coding this field.

Code:

- 1 Alive No evidence or complete remission of cancer
- 2 Alive With any cancer
- 3 Alive Cancer status unknown
- 4 Dead No evidence or complete remission of cancer at death
- 5 Dead This cancer present at death (even if other cancer is also present)
- 6 Dead No evidence or complete remission of this cancer, but another cancer present at death
- 7 Dead Cancer present at death, but it cannot be established whether it was this or another cancer
- 8 Dead Indeterminate whether cancer was present at death

General:

If there is no new follow-up information, the code in Field 25 is the same as on the previous follow-up for this patient. If no follow-up information is ever received, the patient's status at first discharge from the hospital should be coded in Field 25.

It should be emphasized that death certificates are often in error. If the official death certificate does not indicate the presence of cancer although the registry records demonstrate that the patient had cancer at death, this field is to be coded 5, 6, or 7 in accordance with the registry information. Conversely, a death certificate may indicate cancer but receive no support from registry information. In these cases, selection of the best code will depend upon such factors as: how long before death the last follow-up information was obtained, whether it was based upon medical examination, whether the death occurred in a registry hospital, and whether the autopsy findings were available to the registry staff.

Field 26 indicates the primary or underlying cause of death as found on the death certificate or on a listing giving the code number of the underlying cause of death. Even when the death certificate is believed to be in error, the entry as coded by a State Health Department on the death certificate is to be used. The Eighth ICDA, International Classification of Diseases, Adapted for use in the United States, which was published by the U.S. Government Printing Office as Public Health Service Publication No. 1693 was used through December 31, 1978. Beginning with deaths occurring on January 1, 1979, and thereafter the Ninth Revision, International Classification of Diseases, published by the World Health Organization in 1977 is to be used for all deaths.

CP 86-89

Cause of Death Codes as coded on the Death Certificate by the State Health Departments are usually four digits. There are some ICD-9 code numbers that have an optional fifth digit. Ignore the fifth digit.

Through December 31, 1978 the death certificates were coded according to the 8th Revision of the International Classification of Diseases, Adapted. Use E series for violent or accidental deaths. If there is not a fourth digit for the underlying cause of death, use "9" in the fourth digit in CP 89, regardless of whether "x", "blank", or "-" was used.

In some cases a computer listing with causes of death may be supplied by the Health Departments. Be sure to enter the selected underlying cause of death. States using the ACME (Automated Classification of Medical Entities) program usually have several codes on the printouts and then one at the end of the line which the computer has selected as the underlying cause.

As stated above, beginning January 1, 1979, all deaths will be coded by the 9th Revision of ICD. In this volume, "the E code is a supplemental code but will be used as the primary code if, and only if, the morbid condition is classifiable to Chapter XVII (Injury and Poisoning)". Do not include the "E" in the code submitted to SEER.

It is not necessary to have possession of a copy of the death certificate as long as the official code for the underlying cause of death is available. For example, a computer listing may give the underlying cause of death. If the underlying cause is not available, do not attempt to code it; use code 7969. The following SEER codes are considered part of the 7th, 8th, and 9th Revisions for coding Field 26:

CP 86-89 Patient alive at last contact 0000 Death certificate or listing not available 7777 Death certificate or listing available, but underlying cause of death not coded 7969

Page 26.1

Field 26 CP 86-90

,

# Examples:

	ICDA-8 or		
Underlying Cause of Death	ICD-9	CP 86-89	
Cancer of the thyroid	193	1939	
Acute appendicitis with peritonitis	540.0	5400	
Adenocarcinoma of stomach	151.9	1519	
Fell on ice	E885	8859	

CP 90 Blank

Field 27 indicates which revision of the ICD has been used in coding Field 26.

Code:

0 Patient Alive at Last Follow-Up

.

•

- 7 Seventh Revision of ICD
- 8 Eighth Revision of ICDA
- 9 Ninth Revison of ICD

## Code:

1 Case is not in active follow-up

2 Case is (or was) in active follow-up

#### Specific:

- Code 1: "Autopsy Only" or "Death Certificate Only" cases.
- Code 2: Even if the information is incomplete at the time of coding, if the case is being actively followed so that more data will probably become known to the registry, use code "2". Cases coded "2" will be the source data for survival evaluation studies.
  - Note: All alive cases must be actively followed at least annually.

Exception: Cases of carcinoma in-situ of the uterine cervix treated by total hysterectomy need only be followed actively for a period of five years.

# Code:

Non-Specific EOD Code in CP 67-68; blanks in CP 53-66. Scheme A 0 in Field 20 was used to code EOD information.

- Site-Specific Two-Digit Code in CP 67-68; blanks in CP 53-66. 1 Scheme B in Field 20 was used to code EOD information.
- SEER Expanded Site-Specific EOD Code for a specific primary site 2 in CP 53-65; blanks in CP 66-68. Scheme C in Field 2) was used to code EOD information.

Note: Code "0" is obligatory for all "Death Certificate Only" cases.

The purpose of this field is to indicate those combinations of codes in different fields of this record which have already been reviewed for possible error. In effect, coding in this field identifies the improbable combinations which have been found possible. The major utility of Field 30 is to prevent the continuing selection of the case for review after it has already been checked at least once.

The Field is designated as a five-digit field, but at present only CP 94 and 95 are in use. Blanks are to be used in CP 94-98 unless a specific "flag" is warranted.

- CP Code
- 94 Site-Type Edit
  - 1 Reviewed: there is an apparent anomaly between the coding of primary site and histologic type. No need to review again.
- 95 Histology
  - 1 Reviewed: the behavior code of the histology is designated as benign or uncertain in ICD-O but upon review the behavior code remains as in-situ or malignant.



National Cancer Institute NIH Publication No. 79-1999